GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Debt-to-Equity

Hexima (ASX:HXL) Debt-to-Equity : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hexima Debt-to-Equity?

Hexima's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Hexima's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Hexima's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$2.55 Mil. Hexima's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hexima's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of Hexima was 0.01. The lowest was 0.00. And the median was 0.01.

ASX:HXL's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Hexima Debt-to-Equity Historical Data

The historical data trend for Hexima's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Debt-to-Equity Chart

Hexima Annual Data
Trend Jun08 Jun09 Jun10 Jun20 Jun21 Jun22 Jun23
Debt-to-Equity
Get a 7-Day Free Trial - 0.01 0.01 - -

Hexima Semi-Annual Data
Dec06 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hexima's Debt-to-Equity

For the Biotechnology subindustry, Hexima's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hexima's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hexima's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hexima's Debt-to-Equity falls into.



Hexima Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hexima's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Hexima's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hexima  (ASX:HXL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Hexima Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hexima's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hexima (ASX:HXL) Business Description

Traded in Other Exchanges
N/A
Address
84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.